The synthesis of new JNK inhibitors has been pursued to develop efficacious therapeutics for Parkinson’s disease (PD) and other neurodegenerative diseases, such as Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), but also for treatment of myocardial infarction (MI), metabolic disorders, cancer, and inflammatory diseases [33,34]. This evidence concerns the gene MAPK8 and Other metabolic disease.